Literature DB >> 3388726

Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin.

S D Folz1, B L Lee, L H Nowakowski, G A Conder.   

Abstract

The activities of five anticoccidials were compared against Eimeria species in/of chickens, in controlled in vivo and in vitro laboratory studies. Two more recent and potent market entries (maduramicin and halofuginone) were compared with three older polyether antibiotic anticoccidials (monensin, lasalocid and salinomycin). Halofuginone, lasalocid, maduramicin, monensin and salinomycin were evaluated at 3, 125, 5, 120 and 66 ppm, respectively, of active drug in the diets. At these levels, all five drugs demonstrated significant activity against Eimeria tenella, E. maxima, E. necatrix, E. brunetti and E. acervulina (in vivo). Monensin was least effective against E. tenella, and one of the lesser efficacious drugs against E. necatrix, maduramicin, was least effective against E. maxima. In studies of single Eimeria species infections, comparable weight gains were noted for the drugs. In the mixed Eimeria species infections, however, birds treated with maduramicin had significantly higher weight gains than did birds medicated with monensin. Unlike in vivo potencies, titration in vitro indicated that monensin was most potent (active at 10(-6) mcg ml-1), and maduramicin and lasalocid least potent (inactive at less than or equal to 10(-3) mcg ml-1).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3388726     DOI: 10.1016/0304-4017(88)90013-1

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  8 in total

1.  In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.

Authors:  V McDonald; R Stables; D C Warhurst; M R Barer; D A Blewett; H D Chapman; G M Connolly; P L Chiodini; K P McAdam
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Genomics-driven discovery of the biosynthetic gene cluster of maduramicin and its overproduction in Actinomadura sp. J1-007.

Authors:  Ran Liu; Fang Fang; Ziheng An; Renqiong Huang; Yong Wang; Xiao Sun; Shuai Fu; Aisi Fu; Zixin Deng; Tiangang Liu
Journal:  J Ind Microbiol Biotechnol       Date:  2019-12-18       Impact factor: 3.346

3.  Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050.

Authors:  Maxim I Maron; Crystal T Magle; Beata Czesny; Benjamin A Turturice; Ruili Huang; Wei Zheng; Akhil B Vaidya; Kim C Williamson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.

Authors:  Yejin Jang; Jin Soo Shin; Yi-Seul Yoon; Yun Young Go; Hye Won Lee; Oh Seung Kwon; Sehee Park; Man-Seong Park; Meehyein Kim
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

5.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

6.  Effects of polyether ionophores on the protective immune responses of broiler chickens against Angara disease and Newcastle disease viruses.

Authors:  K Munir; M A Muneer; A Tiwari; R M Chaudhry; S Muruganandan
Journal:  Vet Res Commun       Date:  2007-10       Impact factor: 2.816

7.  Maduramicin arrests myocardial cells at G0/G1 phase of the cell cycle through inhibiting AKT-Cyclin D1 signaling.

Authors:  Xin Chen; Chang Liu; Meng Zhang; Yumei Zhang
Journal:  3 Biotech       Date:  2021-06-20       Impact factor: 2.893

Review 8.  Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites.

Authors:  James S Pham; Karen L Dawson; Katherine E Jackson; Erin E Lim; Charisse Flerida A Pasaje; Kelsey E C Turner; Stuart A Ralph
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-11-11       Impact factor: 4.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.